4.7 Article

Magnitude of Enhanced Permeability and Retention Effect in Tumors with Different Phenotypes: 89Zr-Albumin as a Model System

Journal

JOURNAL OF NUCLEAR MEDICINE
Volume 52, Issue 4, Pages 625-633

Publisher

SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.110.083998

Keywords

enhanced permeability and retention (EPR) effect; prostate cancer; albumin; positron emission tomography; Zr-89; contrast-enhanced ultrasound

Funding

  1. Geoffrey Beene Cancer Research Center of Memorial Sloan-Kettering Cancer Center
  2. Office of Science (BER)-U.S. Department of Energy [DE-SC0002456]
  3. NIH [R24-CA83084, P30-CA08748]
  4. German Research Foundation [HE 5432/2-1]

Ask authors/readers for more resources

Targeted nanoparticle-based technologies show increasing prevalence in radiotracer design. As a consequence, quantitative contribution of nonspecific accumulation in the target tissue, mainly governed by the enhanced permeability and retention (EPR) effect, becomes highly relevant for evaluating the specificity of these new agents. This study investigated the influence of different tumor phenotypes on the EPR effect, hypothesizing that a baseline level of uptake must be exceeded to visualize high and specific uptake of a targeted macromolecular radiotracer. Methods: These preliminary studies use Zr-89-labeled mouse serum albumin (Zr-89-desfer-rioxamine-mAlb) as a model radiotracer to assess uptake and retention in 3 xenograft models of human prostate cancer (CWR22rv1, DU-145, and PC-3). Experiments include PET and contrast-enhanced ultrasound imaging to assess morphology, vascularization, and radiotracer uptake; temporal ex vivo biodistribution studies to quantify radiotracer uptake over time; and histologic and autoradiographic studies to evaluate the intra-and intertumoral distribution of Zr-89-desfer-rioxamine-mAlb. Results: Early uptake profiles show statistically significant but overall small differences in radiotracer uptake between different tumor phenotypes. By 20 h, nonspecific radiotracer uptake was found to be independent of tumor size and phenotype, reaching at least 5.0 percentage injected dose per gram in all 3 tumor models. Conclusion: These studies suggest that minimal differences in tumor uptake exist at early time points, dependent on the tumor type. However, these differences equalize over time, reaching around 5.0 percentage injected dose per gram at 20 h after injection. These data provide strong support for the introduction of mandatory experimental controls of future macromolecular or nanoparticle-based drugs, particularly regarding the development of targeted radiotracers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available